Continuous subcutaneous insulin infusion (CSII) in Italy

Diabetes Research and Clinical Practice

Volumn 74, Issue SUPPL. 2, 2006, Pages

  Bruttomesso, Daniela ^a   Costa, Silvana ^a   Crazzolara, Dalia ^a   Di Bartolo, Paolo ^b   Girelli, Angela ^c   Tiengo, Antonio ^a   Italian Study Group on Diffusion of CSII, ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b Presidio Ospedaliero   (Italy)

^c Unita Operativa di Diabetologia   (Italy)

^d NONE

Author keywords

Continuous subcutaneous insulin infusion; Diabetes mellitus; Insulin pump

Indexed keywords

INSULIN; INSULIN DERIVATIVE; POLITEF;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTINUOUS INFUSION; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH CARE ORGANIZATION; HEALTH CENTER; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INJECTION SITE INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NEEDLE; OUTPATIENT CARE; QUESTIONNAIRE;

EID: 33845562456     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(06)70016-X     Document Type: Article

References (5)

1. Bruttomesso D., and Tiengo A. Continuous subcutaneous insulin infusion in Italy, First National Survey. Infusystem 1 (2002) 5-8
2. Garg S.K., Walker A.J., Hoff H.K., D'Souza A.O., Gottlieb P.A., and Chase P. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 6 (2004) 9-15
3. National Institute for Clinical Excellence, Guidance on the use of continuous subcutaneous insulin infusion for diabetes, Technology Appraisal Guidance, No. 57, London, 2003.
4. Selam J.L. Insulin pumps in Europe, Highlights of the International meeting on New technologies for insulin replacement. Session 2 and 4: continuous subcutaneous insulin infusion (CSII). Infusystems International 4 (2005) 17-20
5. Radermecker R.P., and Scheen A.J. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes/Metab Res Rev 20 (2004) 178-188